Experience in clinical using normobact l sinbiotic in combination therapy of acute intestinal infections of virus etiology in children

Abstract

The article presents the results of using Normobact L Synbiotic for the treatment of acute intestinal infections (AII) in children. The study included 60 children aged between 6 months and 6 years with a clinical diagnosis of AII, acute gastroenteritis of viral etiology. The average age of patients enrolled was 2.6 years, with 46.7% (28/60) girls. The treatment of AII was carried out in accordance with the clinical guidelines for the management of acute intestinal infections and included pathogenetic and symptomatic therapy. In addition, the study groupa recieved the biologically active additive (BAA) Normobact L (manufacturer Akrikhin, Russia) containing a probiotic strain Lactodacillus rhamnosus GG. According to the ESPGHAN guidelines, this strain has the largest evidence base of efficacy in the treatment of AII [8]. Synbiotic Normobact L was used at a dose of 1 sachet once daily for 7 days. In the comparison group, the patients received Bifidumbacterin in the amount 15 doses divided into 3 daily intakes for 7 days in addition to pathogenetic and symptomatic therapy. The obtained data analysis showed that diarrheal syndrome ceased earlier in the group of children who received Normobact L. The stool became normal 1.19 days sooner than in the group of children receiving Bifidumbacterin. In general, the period of normalization of stools in Group 1 (Normobact L) was significantly less than in Group 2 (Bifidumbacterin): 3.24 ± 0.4 days and 4.43 ± 0.2 days, respectively. It was also found that the period of normalization of temperature in Group 1 (Normobact L) was significantly less than in Group 2 (Bifidumbacterin): 53.00 ± 1.98 and 78.3 ± 2.44 h respectively. The body temperature in 100% of patients in the group of children receiving Normobact L became normal on Day 5, in the group of children receiving Bifidumbacterin on Day 7.